Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.34 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6131675 | 0.91 | MAPT (0.37) | L3MBTL1KMT2AMAPTKCNJ1SMN1; SMN2 | |
| SCHEMBL6131693 | 0.88 | L3MBTL1 (0.36) | L3MBTL1KMT2AITGA4ITGB7MAPT | |
| SCHEMBL6131690 | 0.87 | PPID (0.34) | KMT2AADRB2ADRB1ADRB3ITGA4 | |
| SCHEMBL6532346 | 0.81 | ITGB1 (0.41) | L3MBTL1KMT2AMEN1ITGA4MAPT | |
| SCHEMBL6131686 | 0.77 | PPID (0.41) | ITGA4ITGB7BACE1 | |
| SCHEMBL6131661 | 0.76 | ITGB1 (0.50) | KMT2AMEN1ITGA4MAPT | |
| SCHEMBL6131662 | 0.76 | ITGB1 (0.50) | KMT2AMEN1ITGA4MAPT | |
| SCHEMBL4734050 | 0.74 | LMNA (0.41) | L3MBTL1KMT2AMEN1ITGA4MAPT | |
| SCHEMBL6131691 | 0.74 | CTSC (0.34) | ITGA4ITGB7HDAC1 | |
| SCHEMBL4737032 | 0.74 | BCHE (0.41) | KMT2AMEN1ITGA4ITGB7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951943-B2 | Process for the preparation of phenylalanine enamide derivatives | CELLTECH R & D LIMITED (GB) | 2005-10-04 | — | — | US | claimed |
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2004-04-15 | — | — | US | claimed |
| US-6951943-B2 | Process for the preparation of phenylalanine enamide derivatives | CELLTECH R & D LIMITED (GB) | 2005-10-04 | — | — | US | disclosed |
| EP-1525181-A1 | PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES | Celltech R & D Limited (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | UCB PHARMA S.A. (BE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004007428-A1 | PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073033-A1 | Process for the preparation of phenylalanine enamide derivatives | NPY2R, NPY1R, NPR1 | L3MBTL1 1306/4885KMT2A 1241/4885ADRB2 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.